25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Mezzion Pharma Co.Ltd
Buy, Hold or Sell?

Let's analyze Mezzion together

I guess you are interested in Mezzion Pharma Co.Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Mezzion Pharma Co.Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Mezzion Pharma Co.Ltd

I send you an email if I find something interesting about Mezzion Pharma Co.Ltd.

1. Quick Overview

1.1. Quick analysis of Mezzion (30 sec.)










1.2. What can you expect buying and holding a share of Mezzion? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
₩1,850.93
Expected worth in 1 year
₩1,435.33
How sure are you?
32.4%

+ What do you gain per year?

Total Gains per Share
₩-415.60
Return On Investment
-1.3%

For what price can you sell your share?

Current Price per Share
₩30,950.00
Expected price per share
₩27,000 - ₩36,100
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Mezzion (5 min.)




Live pricePrice per Share (EOD)
₩30,950.00
Intrinsic Value Per Share
₩-20,485.80 - ₩-24,391.58
Total Value Per Share
₩-18,634.86 - ₩-22,540.65

2.2. Growth of Mezzion (5 min.)




Is Mezzion growing?

Current yearPrevious yearGrowGrow %
How rich?$38.5m$26m$15.5m37.4%

How much money is Mezzion making?

Current yearPrevious yearGrowGrow %
Making money-$1.5m-$3.7m$2.1m140.8%
Net Profit Margin-41.4%-68.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Mezzion (5 min.)




2.4. Comparing to competitors in the Pharmaceuticals industry (5 min.)




  Industry Rankings (Pharmaceuticals)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Mezzion?

Welcome investor! Mezzion's management wants to use your money to grow the business. In return you get a share of Mezzion.

First you should know what it really means to hold a share of Mezzion. And how you can make/lose money.

Speculation

The Price per Share of Mezzion is ₩30,950. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Mezzion.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Mezzion, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩1,850.93. Based on the TTM, the Book Value Change Per Share is ₩-103.90 per quarter. Based on the YOY, the Book Value Change Per Share is ₩200.47 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Mezzion.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.040.0%-0.050.0%-0.140.0%-0.160.0%-0.180.0%
Usd Book Value Change Per Share-0.070.0%-0.070.0%0.140.0%-0.160.0%0.040.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.070.0%-0.070.0%0.140.0%-0.160.0%0.040.0%
Usd Price Per Share25.97-27.52-13.92-70.58-56.26-
Price to Earnings Ratio-170.56-878.67--24.61-105.29-49.65-
Price-to-Total Gains Ratio-397.01--387.90--47.13--190.17--40.04-
Price to Book Ratio20.04-19.61-14.97-54.25-35.21-
Price-to-Total Gains Ratio-397.01--387.90--47.13--190.17--40.04-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share21.665
Number of shares46
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.07-0.16
Usd Total Gains Per Share-0.07-0.16
Gains per Quarter (46 shares)-3.35-7.38
Gains per Year (46 shares)-13.38-29.54
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-13-230-30-40
20-27-360-59-70
30-40-490-89-100
40-54-620-118-130
50-67-750-148-160
60-80-880-177-190
70-94-1010-207-220
80-107-1140-236-250
90-120-1270-266-280
100-134-1400-295-310

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%3.026.05.08.8%3.026.05.08.8%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%4.016.00.020.0%11.023.00.032.4%11.023.00.032.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.034.00.0%0.00.034.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%4.016.00.020.0%11.023.00.032.4%11.023.00.032.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Mezzion Pharma Co.Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---93.447-103.900+11%200.470-147%-229.337+145%54.439-272%
Book Value Per Share--1850.9332007.449-8%1334.386+39%2096.714-12%3805.470-51%
Current Ratio--2.6482.594+2%2.369+12%3.051-13%3.208-17%
Debt To Asset Ratio--0.2890.320-10%0.437-34%0.330-12%0.332-13%
Debt To Equity Ratio--0.4070.472-14%0.847-52%0.522-22%0.528-23%
Dividend Per Share----0%-0%-0%-0%
Eps---54.380-74.822+38%-197.126+262%-230.165+323%-263.273+384%
Free Cash Flow Per Share---434.999-221.578-49%-143.139-67%-287.603-34%-407.380-6%
Free Cash Flow To Equity Per Share---434.999-221.578-49%248.471-275%-43.334-90%-280.520-36%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.853+17%
Intrinsic Value_10Y_max---24391.584--------
Intrinsic Value_10Y_min---20485.798--------
Intrinsic Value_1Y_max---923.133--------
Intrinsic Value_1Y_min---905.846--------
Intrinsic Value_3Y_max---3932.877--------
Intrinsic Value_3Y_min---3731.247--------
Intrinsic Value_5Y_max---8340.230--------
Intrinsic Value_5Y_min---7641.412--------
Market Cap264508294500.000-317%1103896661700.0001166010056412.500-5%557422216850.000+98%2417176557002.500-54%1602254930369.118-31%
Net Profit Margin---0.713-0.414-42%-0.685-4%-0.715+0%-0.767+7%
Operating Margin----0%-0.1140%-0.2880%-0.6360%
Operating Ratio--3.8133.005+27%1.960+95%1.620+135%1.988+92%
Pb Ratio16.721-20%20.04419.611+2%14.973+34%54.255-63%35.212-43%
Pe Ratio-142.285+17%-170.558878.668-119%-24.608-86%105.292-262%49.652-444%
Price Per Share30950.000-20%37100.00039312.500-6%19892.500+87%100831.000-63%80375.588-54%
Price To Free Cash Flow Ratio-17.787+17%-21.322-135.287+534%-42.468+99%-135.711+536%-79.325+272%
Price To Total Gains Ratio-331.202+17%-397.015-387.896-2%-47.131-88%-190.170-52%-40.039-90%
Quick Ratio--0.8900.802+11%2.256-61%2.818-68%2.203-60%
Return On Assets---0.021-0.025+19%-0.096+360%-0.075+259%-0.059+184%
Return On Equity---0.029-0.037+25%-0.196+568%-0.122+315%-0.092+214%
Total Gains Per Share---93.447-103.900+11%200.470-147%-229.337+145%54.439-272%
Usd Book Value--38551670.21341676237.036-7%26076435.264+48%33169948.844+16%34919597.677+10%
Usd Book Value Change Per Share---0.065-0.073+11%0.140-147%-0.161+145%0.038-272%
Usd Book Value Per Share--1.2961.405-8%0.934+39%1.468-12%2.664-51%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.038-0.052+38%-0.138+262%-0.161+323%-0.184+384%
Usd Free Cash Flow---9060259.327-4606082.875-49%-2819905.412-69%-3515857.961-61%-3137901.756-65%
Usd Free Cash Flow Per Share---0.304-0.155-49%-0.100-67%-0.201-34%-0.285-6%
Usd Free Cash Flow To Equity Per Share---0.304-0.155-49%0.174-275%-0.030-90%-0.196-36%
Usd Market Cap185155806.150-317%772727663.190816207039.489-5%390195551.795+98%1692023589.902-54%1121578451.258-31%
Usd Price Per Share21.665-20%25.97027.519-6%13.925+87%70.582-63%56.263-54%
Usd Profit---1132647.285-1551942.338+37%-3737795.290+230%-3250992.433+187%-2678926.377+137%
Usd Revenue--1588072.2553543053.969-55%5545020.931-71%4609685.592-66%3588459.016-56%
Usd Total Gains Per Share---0.065-0.073+11%0.140-147%-0.161+145%0.038-272%
 EOD+3 -5MRQTTM+15 -17YOY+15 -175Y+16 -1610Y+13 -20

3.3 Fundamental Score

Let's check the fundamental score of Mezzion Pharma Co.Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-142.285
Price to Book Ratio (EOD)Between0-116.721
Net Profit Margin (MRQ)Greater than0-0.713
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.890
Current Ratio (MRQ)Greater than12.648
Debt to Asset Ratio (MRQ)Less than10.289
Debt to Equity Ratio (MRQ)Less than10.407
Return on Equity (MRQ)Greater than0.15-0.029
Return on Assets (MRQ)Greater than0.05-0.021
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Mezzion Pharma Co.Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.653
Ma 20Greater thanMa 5032,317.500
Ma 50Greater thanMa 10030,973.000
Ma 100Greater thanMa 20032,538.500
OpenGreater thanClose31,800.000
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Mezzion Pharma Co.Ltd

Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-11-19 04:19:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Mezzion earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Mezzion to the Pharmaceuticals industry mean.
  • A Net Profit Margin of -71.3% means that ₩-0.71 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Mezzion Pharma Co.Ltd:

  • The MRQ is -71.3%. The company is making a huge loss. -2
  • The TTM is -41.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-71.3%TTM-41.4%-30.0%
TTM-41.4%YOY-68.5%+27.2%
TTM-41.4%5Y-71.5%+30.1%
5Y-71.5%10Y-76.7%+5.2%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-71.3%9.8%-81.1%
TTM-41.4%9.5%-50.9%
YOY-68.5%9.9%-78.4%
5Y-71.5%12.9%-84.4%
10Y-76.7%12.6%-89.3%
4.3.1.2. Return on Assets

Shows how efficient Mezzion is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Mezzion to the Pharmaceuticals industry mean.
  • -2.1% Return on Assets means that Mezzion generated ₩-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Mezzion Pharma Co.Ltd:

  • The MRQ is -2.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -2.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.1%TTM-2.5%+0.4%
TTM-2.5%YOY-9.6%+7.1%
TTM-2.5%5Y-7.5%+5.0%
5Y-7.5%10Y-5.9%-1.6%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.1%3.6%-5.7%
TTM-2.5%3.5%-6.0%
YOY-9.6%5.3%-14.9%
5Y-7.5%5.9%-13.4%
10Y-5.9%4.9%-10.8%
4.3.1.3. Return on Equity

Shows how efficient Mezzion is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Mezzion to the Pharmaceuticals industry mean.
  • -2.9% Return on Equity means Mezzion generated ₩-0.03 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Mezzion Pharma Co.Ltd:

  • The MRQ is -2.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -3.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.9%TTM-3.7%+0.7%
TTM-3.7%YOY-19.6%+15.9%
TTM-3.7%5Y-12.2%+8.5%
5Y-12.2%10Y-9.2%-3.0%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.9%4.6%-7.5%
TTM-3.7%4.6%-8.3%
YOY-19.6%8.2%-27.8%
5Y-12.2%9.1%-21.3%
10Y-9.2%10.3%-19.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Mezzion Pharma Co.Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Mezzion is operating .

  • Measures how much profit Mezzion makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Mezzion to the Pharmaceuticals industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Mezzion Pharma Co.Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-11.4%+11.4%
TTM-5Y-28.8%+28.8%
5Y-28.8%10Y-63.6%+34.9%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.2%-13.2%
TTM-12.0%-12.0%
YOY-11.4%12.4%-23.8%
5Y-28.8%8.6%-37.4%
10Y-63.6%12.1%-75.7%
4.3.2.2. Operating Ratio

Measures how efficient Mezzion is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • An Operation Ratio of 3.81 means that the operating costs are ₩3.81 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Mezzion Pharma Co.Ltd:

  • The MRQ is 3.813. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.005. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.813TTM3.005+0.808
TTM3.005YOY1.960+1.045
TTM3.0055Y1.620+1.385
5Y1.62010Y1.988-0.369
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8131.225+2.588
TTM3.0051.220+1.785
YOY1.9601.311+0.649
5Y1.6201.249+0.371
10Y1.9881.240+0.748
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Mezzion Pharma Co.Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Mezzion is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A Current Ratio of 2.65 means the company has ₩2.65 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Mezzion Pharma Co.Ltd:

  • The MRQ is 2.648. The company is able to pay all its short-term debts. +1
  • The TTM is 2.594. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.648TTM2.594+0.054
TTM2.594YOY2.369+0.226
TTM2.5945Y3.051-0.456
5Y3.05110Y3.208-0.157
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6482.213+0.435
TTM2.5942.234+0.360
YOY2.3692.028+0.341
5Y3.0512.199+0.852
10Y3.2081.995+1.213
4.4.3.2. Quick Ratio

Measures if Mezzion is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Mezzion to the Pharmaceuticals industry mean.
  • A Quick Ratio of 0.89 means the company can pay off ₩0.89 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Mezzion Pharma Co.Ltd:

  • The MRQ is 0.890. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.802. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.890TTM0.802+0.088
TTM0.802YOY2.256-1.454
TTM0.8025Y2.818-2.015
5Y2.81810Y2.203+0.615
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8900.926-0.036
TTM0.8020.973-0.171
YOY2.2561.515+0.741
5Y2.8181.591+1.227
10Y2.2031.399+0.804
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Mezzion Pharma Co.Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Mezzion assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Mezzion to Pharmaceuticals industry mean.
  • A Debt to Asset Ratio of 0.29 means that Mezzion assets are financed with 28.9% credit (debt) and the remaining percentage (100% - 28.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Mezzion Pharma Co.Ltd:

  • The MRQ is 0.289. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.320. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.289TTM0.320-0.031
TTM0.320YOY0.437-0.117
TTM0.3205Y0.330-0.010
5Y0.33010Y0.332-0.002
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2890.345-0.056
TTM0.3200.339-0.019
YOY0.4370.333+0.104
5Y0.3300.315+0.015
10Y0.3320.339-0.007
4.5.4.2. Debt to Equity Ratio

Measures if Mezzion is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Mezzion to the Pharmaceuticals industry mean.
  • A Debt to Equity ratio of 40.7% means that company has ₩0.41 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Mezzion Pharma Co.Ltd:

  • The MRQ is 0.407. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.472. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.407TTM0.472-0.065
TTM0.472YOY0.847-0.375
TTM0.4725Y0.522-0.050
5Y0.52210Y0.528-0.006
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4070.547-0.140
TTM0.4720.547-0.075
YOY0.8470.499+0.348
5Y0.5220.476+0.046
10Y0.5280.548-0.020
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Mezzion generates.

  • Above 15 is considered overpriced but always compare Mezzion to the Pharmaceuticals industry mean.
  • A PE ratio of -170.56 means the investor is paying ₩-170.56 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Mezzion Pharma Co.Ltd:

  • The EOD is -142.285. Based on the earnings, the company is expensive. -2
  • The MRQ is -170.558. Based on the earnings, the company is expensive. -2
  • The TTM is 878.668. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-142.285MRQ-170.558+28.273
MRQ-170.558TTM878.668-1,049.225
TTM878.668YOY-24.608+903.276
TTM878.6685Y105.292+773.376
5Y105.29210Y49.652+55.639
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD-142.28527.863-170.148
MRQ-170.55829.844-200.402
TTM878.66827.532+851.136
YOY-24.60823.102-47.710
5Y105.29227.577+77.715
10Y49.65229.248+20.404
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Mezzion Pharma Co.Ltd:

  • The EOD is -17.787. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -21.322. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -135.287. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-17.787MRQ-21.322+3.534
MRQ-21.322TTM-135.287+113.965
TTM-135.287YOY-42.468-92.819
TTM-135.2875Y-135.711+0.424
5Y-135.71110Y-79.325-56.386
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD-17.78739.245-57.032
MRQ-21.32229.531-50.853
TTM-135.28729.447-164.734
YOY-42.46826.360-68.828
5Y-135.71131.734-167.445
10Y-79.32534.357-113.682
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Mezzion is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A PB ratio of 20.04 means the investor is paying ₩20.04 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Mezzion Pharma Co.Ltd:

  • The EOD is 16.721. Based on the equity, the company is expensive. -2
  • The MRQ is 20.044. Based on the equity, the company is expensive. -2
  • The TTM is 19.611. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD16.721MRQ20.044-3.323
MRQ20.044TTM19.611+0.433
TTM19.611YOY14.973+4.638
TTM19.6115Y54.255-34.644
5Y54.25510Y35.212+19.043
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD16.7214.659+12.062
MRQ20.0443.381+16.663
TTM19.6113.209+16.402
YOY14.9732.597+12.376
5Y54.2553.278+50.977
10Y35.2124.179+31.033
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in KRW. All numbers in thousands.

Summary
Total Assets77,479,880
Total Liabilities22,406,065
Total Stockholder Equity55,073,815
 As reported
Total Liabilities 22,406,065
Total Stockholder Equity+ 55,073,815
Total Assets = 77,479,880

Assets

Total Assets77,479,880
Total Current Assets56,906,692
Long-term Assets20,573,188
Total Current Assets
Cash And Cash Equivalents 23,122,455
Short-term Investments 18,000,000
Net Receivables 1,130,956
Inventory 5,520,853
Total Current Assets  (as reported)56,906,692
Total Current Assets  (calculated)47,774,265
+/- 9,132,427
Long-term Assets
Property Plant Equipment 2,988,557
Intangible Assets 16,556,177
Long-term Assets  (as reported)20,573,188
Long-term Assets  (calculated)19,544,734
+/- 1,028,454

Liabilities & Shareholders' Equity

Total Current Liabilities21,490,607
Long-term Liabilities915,458
Total Stockholder Equity55,073,815
Total Current Liabilities
Accounts payable 1,869,372
Other Current Liabilities -1
Total Current Liabilities  (as reported)21,490,607
Total Current Liabilities  (calculated)1,869,371
+/- 19,621,236
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt732,034
Long-term Liabilities  (as reported)915,458
Long-term Liabilities  (calculated)732,034
+/- 183,424
Total Stockholder Equity
Total Stockholder Equity (as reported)55,073,815
Total Stockholder Equity (calculated)0
+/- 55,073,815
Other
Capital Stock14,912,206
Common Stock Shares Outstanding 29,755
Net Invested Capital 55,073,815
Net Working Capital 35,416,085
Property Plant and Equipment Gross 2,988,557



6.2. Balance Sheets Structured

Currency in KRW. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-31
> Total Assets 
102,632,326
99,700,859
95,050,555
95,899,262
89,881,712
86,827,183
62,221,993
74,038,036
72,732,373
68,303,492
77,750,213
75,059,445
75,558,956
71,581,184
66,756,048
58,873,712
55,934,751
50,281,863
46,287,491
75,625,434
69,438,838
71,774,113
68,079,575
83,934,574
81,141,439
63,304,813
60,951,326
54,021,841
48,378,716
88,663,789
93,400,751
92,149,354
87,719,289
77,479,880
77,479,88087,719,28992,149,35493,400,75188,663,78948,378,71654,021,84160,951,32663,304,81381,141,43983,934,57468,079,57571,774,11369,438,83875,625,43446,287,49150,281,86355,934,75158,873,71266,756,04871,581,18475,558,95675,059,44577,750,21368,303,49272,732,37374,038,03662,221,99386,827,18389,881,71295,899,26295,050,55599,700,859102,632,326
   > Total Current Assets 
0
0
0
0
0
85,235,602
59,322,968
70,500,591
69,077,605
64,794,207
73,046,391
70,018,630
67,445,443
62,187,533
57,210,833
51,849,133
49,122,465
43,515,681
37,584,871
60,668,763
54,384,177
55,237,904
50,544,405
64,174,205
60,135,731
56,111,571
52,920,066
45,897,007
40,552,075
80,646,211
78,936,717
74,243,516
67,811,690
56,906,692
56,906,69267,811,69074,243,51678,936,71780,646,21140,552,07545,897,00752,920,06656,111,57160,135,73164,174,20550,544,40555,237,90454,384,17760,668,76337,584,87143,515,68149,122,46551,849,13357,210,83362,187,53367,445,44370,018,63073,046,39164,794,20769,077,60570,500,59159,322,96885,235,60200000
       Cash And Cash Equivalents 
0
0
0
0
0
41,712,630
30,211,182
32,067,979
25,454,884
21,530,139
24,098,700
29,551,187
28,605,621
24,447,585
15,751,686
11,201,886
5,328,037
3,397,640
2,352,328
33,947,816
25,994,101
20,399,178
14,959,493
1,795
1,481
2,742
1,984
1,460
2,824
1,820
41,501,511
40,246,153
35,634,660
23,122,455
23,122,45535,634,66040,246,15341,501,5111,8202,8241,4601,9842,7421,4811,79514,959,49320,399,17825,994,10133,947,8162,352,3283,397,6405,328,03711,201,88615,751,68624,447,58528,605,62129,551,18724,098,70021,530,13925,454,88432,067,97930,211,18241,712,63000000
       Short-term Investments 
0
0
0
0
0
28,864,000
21,041,559
20,833,535
20,861,233
21,750,721
23,324,926
25,861,233
24,421,290
20,500,000
25,342,062
0
0
0
18,027,084
13,250,000
13,000,001
13,000,000
13,000,000
23,000,000
23,000,000
13,000,000
3,000,000
3,000,000
3,000,000
23,000,000
23,000,000
18,000,000
18,000,000
18,000,000
18,000,00018,000,00018,000,00023,000,00023,000,0003,000,0003,000,0003,000,00013,000,00023,000,00023,000,00013,000,00013,000,00013,000,00113,250,00018,027,08400025,342,06220,500,00024,421,29025,861,23323,324,92621,750,72120,861,23320,833,53521,041,55928,864,00000000
       Net Receivables 
1,049,122
2,245,223
1,069,704
1,745,211
1,361,132
1,126,811
963,611
1,964,299
2,468,426
2,044,543
2,092,824
6,620,306
6,522,458
2,051,726
2,462,733
4,199,826
3,133,664
2,993,005
3,183,285
4,248,372
5,161,245
5,543,562
5,647,088
4,434,935
4,377,069
4,627,639
4,510,093
2,676,919
3,066,214
3,156,890
3,661,224
2,308,899
1,100,904
1,130,956
1,130,9561,100,9042,308,8993,661,2243,156,8903,066,2142,676,9194,510,0934,627,6394,377,0694,434,9355,647,0885,543,5625,161,2454,248,3723,183,2852,993,0053,133,6644,199,8262,462,7332,051,7266,522,4586,620,3062,092,8242,044,5432,468,4261,964,299963,6111,126,8111,361,1321,745,2111,069,7042,245,2231,049,122
       Other Current Assets 
433,119
701,260
1,776,283
798,283
616,422
1,451,860
3,143,363
2,846,986
11,671,567
4,940,196
5,490,430
17,770
86,136
305,050
5,949,760
235,105
516,640
780,032
348,899
66,805
81,310
182,372
328,047
201,296
311,361
294,239
391,909
1
-14,775,337
1
-1
1
1
0
011-11-14,775,3371391,909294,239311,361201,296328,047182,37281,31066,805348,899780,032516,640235,1055,949,760305,05086,13617,7705,490,4304,940,19611,671,5672,846,9863,143,3631,451,860616,422798,2831,776,283701,260433,119
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,124,835
7,826,641
8,017,578
14,464,034
17,905,838
19,907,599
20,573,188
20,573,18819,907,59917,905,83814,464,0348,017,5787,826,6418,124,835000000000000000000000000000
       Property Plant Equipment 
697,515
648,369
596,823
203,275
192,029
179,417
168,905
860,759
851,826
889,870
1,508,209
1,200,249
4,285,290
5,366,726
5,354,745
4,902,374
4,683,037
4,509,521
6,256,619
5,898,905
5,581,151
5,186,714
4,975,232
4,878,808
4,983,193
4,739,142
4,644,131
4,244,629
3,298,199
3,869,488
4,619,930
2,854,251
3,097,581
2,988,557
2,988,5573,097,5812,854,2514,619,9303,869,4883,298,1994,244,6294,644,1314,739,1424,983,1934,878,8084,975,2325,186,7145,581,1515,898,9056,256,6194,509,5214,683,0374,902,3745,354,7455,366,7264,285,2901,200,2491,508,209889,870851,826860,759168,905179,417192,029203,275596,823648,369697,515
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
554,920
0
0
684,275
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000684,27500554,9200000000000
       Intangible Assets 
2,476,971
1,922,361
1,867,750
306,712
306,712
306,712
1,635,312
1,635,312
1,635,312
1,635,312
1,635,312
1,635,312
1,635,312
1,635,312
1,635,312
1,619,740
1,619,740
1,619,740
1,619,740
8,241,606
8,651,975
10,371,830
11,572,681
14,178,632
15,318,043
1,619,740
2,535,674
1,619,740
1,619,740
2,082,885
7,739,006
12,943,311
16,056,327
16,556,177
16,556,17716,056,32712,943,3117,739,0062,082,8851,619,7401,619,7402,535,6741,619,74015,318,04314,178,63211,572,68110,371,8308,651,9758,241,6061,619,7401,619,7401,619,7401,619,7401,635,3121,635,3121,635,3121,635,3121,635,3121,635,3121,635,3121,635,3121,635,312306,712306,712306,7121,867,7501,922,3612,476,971
> Total Liabilities 
43,261,039
43,490,410
42,424,217
43,089,944
40,395,903
38,163,152
16,708,623
20,868,778
18,731,729
21,100,925
21,310,337
17,740,343
15,703,988
15,866,281
13,788,446
16,043,627
17,761,510
16,890,142
17,612,820
18,815,705
20,271,155
21,094,732
20,724,918
21,141,075
22,596,785
24,137,037
26,923,249
27,781,789
26,521,880
21,780,552
29,516,357
30,704,991
29,971,934
22,406,065
22,406,06529,971,93430,704,99129,516,35721,780,55226,521,88027,781,78926,923,24924,137,03722,596,78521,141,07520,724,91821,094,73220,271,15518,815,70517,612,82016,890,14217,761,51016,043,62713,788,44615,866,28115,703,98817,740,34321,310,33721,100,92518,731,72920,868,77816,708,62338,163,15240,395,90343,089,94442,424,21743,490,41043,261,039
   > Total Current Liabilities 
15,772,212
15,498,697
15,225,725
16,480,745
12,958,550
9,630,084
5,002,178
20,493,110
18,731,729
21,100,925
21,310,337
17,740,343
13,324,487
13,215,735
10,767,527
13,509,662
14,963,632
14,425,073
13,999,699
15,514,221
13,184,491
17,975,173
17,659,286
18,496,575
20,030,709
21,725,521
24,623,091
26,080,011
25,032,991
20,441,706
27,399,334
29,615,263
28,961,737
21,490,607
21,490,60728,961,73729,615,26327,399,33420,441,70625,032,99126,080,01124,623,09121,725,52120,030,70918,496,57517,659,28617,975,17313,184,49115,514,22113,999,69914,425,07314,963,63213,509,66210,767,52713,215,73513,324,48717,740,34321,310,33721,100,92518,731,72920,493,1105,002,1789,630,08412,958,55016,480,74515,225,72515,498,69715,772,212
       Short-term Debt 
0
0
0
0
0
27,850,515
10,930,915
8,174,842
4,557,157
3,200,365
0
0
0
0
188,429
424,620
482,675
831,864
1,007,182
985,499
387,636
1,348,109
660,122
932,014
1,086,925
1,351,205
1,535,504
1,062,980
695,935
868,710
0
0
0
0
0000868,710695,9351,062,9801,535,5041,351,2051,086,925932,014660,1221,348,109387,636985,4991,007,182831,864482,675424,620188,42900003,200,3654,557,1578,174,84210,930,91527,850,51500000
       Short Long Term Debt 
0
0
0
0
0
27,850,515
10,930,915
8,174,842
4,557,157
3,200,365
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,062,980
695,935
868,710
790,337
499,577
719,794
0
0719,794499,577790,337868,710695,9351,062,980000000000000000003,200,3654,557,1578,174,84210,930,91527,850,51500000
       Accounts payable 
2,727,871
2,450,890
2,301,519
3,444,055
2,234,505
1,111,201
0
2,468,885
4,042,946
0
0
2,992,945
0
2,416,219
2,214,206
3,573,809
2,858,630
3,473,766
5,733,573
3,465,738
3,292,627
6,939,890
7,505,046
5,503,011
5,165,382
6,143,930
0
7,172,824
5,609,424
3,331,772
5,318,993
4,030,004
1,759,480
1,869,372
1,869,3721,759,4804,030,0045,318,9933,331,7725,609,4247,172,82406,143,9305,165,3825,503,0117,505,0466,939,8903,292,6273,465,7385,733,5733,473,7662,858,6303,573,8092,214,2062,416,21902,992,945004,042,9462,468,88501,111,2012,234,5053,444,0552,301,5192,450,8902,727,871
       Other Current Liabilities 
13,044,341
12,166,499
12,924,206
13,036,690
10,724,045
8,518,883
5,002,178
9,849,383
10,131,626
17,900,560
9,588,972
6,867,764
9,756,967
5,395,041
2,494,070
908,039
3,147,749
834,615
798,036
4,515,136
4,163,766
8,637,826
3,796,106
3,822,595
4,007,067
3,628,022
9,975,983
0
-1
1
-1
444,551
0
-1
-10444,551-11-109,975,9833,628,0224,007,0673,822,5953,796,1068,637,8264,163,7664,515,136798,036834,6153,147,749908,0392,494,0705,395,0419,756,9676,867,7649,588,97217,900,56010,131,6269,849,3835,002,1788,518,88310,724,04513,036,69012,924,20612,166,49913,044,341
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,701,778
1,488,889
1,338,847
2,117,022
1,089,728
1,010,198
915,458
915,4581,010,1981,089,7282,117,0221,338,8471,488,8891,701,778000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,936,552
2,419,534
2,353,473
2,235,179
0
3,103,938
2,821,870
2,665,495
2,560,175
2,337,516
2,189,963
2,020,842
1,841,791
1,624,949
1,410,546
1,258,960
0
0
0
0
00001,258,9601,410,5461,624,9491,841,7912,020,8422,189,9632,337,5162,560,1752,665,4952,821,8703,103,93802,235,1792,353,4732,419,5342,936,55200000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
-27,850,515
-10,930,915
-8,174,842
-4,557,157
-3,200,365
0
0
0
0
-188,429
-424,620
-482,675
-831,864
-1,007,182
-985,499
-387,636
-1,348,109
-660,122
-932,014
-1,086,925
-1,351,205
-1,535,504
1,587,842
1,474,670
1,353,344
3,060,624
0
734,165
732,034
732,034734,16503,060,6241,353,3441,474,6701,587,842-1,535,504-1,351,205-1,086,925-932,014-660,122-1,348,109-387,636-985,499-1,007,182-831,864-482,675-424,620-188,4290000-3,200,365-4,557,157-8,174,842-10,930,915-27,850,51500000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,621,866
7,032,235
8,752,090
9,952,942
12,558,893
13,698,303
0
915,934
0
0
0
0
0
0
0
0000000915,934013,698,30312,558,8939,952,9428,752,0907,032,2356,621,8660000000000000000000
> Total Stockholder Equity
59,371,287
56,210,449
52,626,338
52,809,318
49,485,809
48,664,031
45,513,370
53,169,258
54,000,644
47,202,567
56,439,876
57,319,103
59,854,968
55,714,903
52,967,602
42,830,085
38,173,240
33,391,721
28,674,671
56,809,729
49,167,682
50,679,381
47,354,656
62,793,498
58,544,654
39,167,776
34,028,076
26,240,053
21,856,836
66,883,237
63,884,394
61,444,363
57,747,355
55,073,815
55,073,81557,747,35561,444,36363,884,39466,883,23721,856,83626,240,05334,028,07639,167,77658,544,65462,793,49847,354,65650,679,38149,167,68256,809,72928,674,67133,391,72138,173,24042,830,08552,967,60255,714,90359,854,96857,319,10356,439,87647,202,56754,000,64453,169,25845,513,37048,664,03149,485,80952,809,31852,626,33856,210,44959,371,287
   Common Stock
4,079,000
4,079,000
4,079,000
4,079,000
4,079,000
4,079,000
4,082,676
4,171,155
4,268,719
4,309,090
4,309,090
4,320,854
4,327,226
4,327,226
4,352,976
4,352,976
4,352,976
4,352,976
4,352,976
4,446,353
4,446,353
4,446,353
4,450,103
4,450,503
4,457,003
13,371,009
13,371,009
13,371,009
13,371,009
14,754,518
0
0
0
0
000014,754,51813,371,00913,371,00913,371,00913,371,0094,457,0034,450,5034,450,1034,446,3534,446,3534,446,3534,352,9764,352,9764,352,9764,352,9764,352,9764,327,2264,327,2264,320,8544,309,0904,309,0904,268,7194,171,1554,082,6764,079,0004,079,0004,079,0004,079,0004,079,0004,079,000
   Retained Earnings 
19,075,113
150,036
10,356,832
150,036
5,153,825
195,087
275,619
404,678
598,513
-15,893,702
-20,423,954
-24,113,338
-28,106,209
-32,484,853
-35,798,966
-47,351,138
-50,458,250
-56,206,056
-62,070,749
-61,166,478
-67,420,083
-66,843,879
-68,446,426
-74,788,579
-79,006,417
-95,104,687
-92,958,997
-111,052,473
-113,561,879
-116,478,084
-117,463,832
-123,723,165
-123,669,824
-125,234,582
-125,234,582-123,669,824-123,723,165-117,463,832-116,478,084-113,561,879-111,052,473-92,958,997-95,104,687-79,006,417-74,788,579-68,446,426-66,843,879-67,420,083-61,166,478-62,070,749-56,206,056-50,458,250-47,351,138-35,798,966-32,484,853-28,106,209-24,113,338-20,423,954-15,893,702598,513404,678275,619195,0875,153,825150,03610,356,832150,03619,075,113
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
66,705,824
67,282,607
67,299,646
67,650,221
67,964,525
92,836,190
93,179,447
93,744,969
94,488,188
88,249,091
88,617,900
79,703,894
79,703,894
79,703,894
79,703,894
126,807,273
0
0
0
0
0000126,807,27379,703,89479,703,89479,703,89479,703,89488,617,90088,249,09194,488,18893,744,96993,179,44792,836,19067,964,52567,650,22167,299,64667,282,60766,705,82400000000000000
   Treasury Stock00000000000000000000000-2,307,289-8,708,388-8,708,388-8,708,388-16,816,449-16,816,449-16,816,448-16,816,448-16,816,448-16,816,448-16,816,449
   Other Stockholders Equity 
0
0
0
0
0
-274,535
-170,092
-130,068
68,438
119,220
406,460
972,642
1,402,669
1,640,778
17,707,769
2,864,814
1,315,081
2,281,368
3,429,011
5,999,486
4,611,045
5,546,540
3,612,913
25,329,893
24,923,577
21,644,970
14,359,580
35,644,681
33,398,861
32,854,579
0
0
0
0
000032,854,57933,398,86135,644,68114,359,58021,644,97024,923,57725,329,8933,612,9135,546,5404,611,0455,999,4863,429,0112,281,3681,315,0812,864,81417,707,7691,640,7781,402,669972,642406,460119,22068,438-130,068-170,092-274,53500000



6.3. Balance Sheets

Currency in KRW. All numbers in thousands.




6.4. Cash Flows

Currency in KRW. All numbers in thousands.




6.5. Income Statements

Currency in KRW. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in KRW. All numbers in thousands.

Gross Profit (+$)
totalRevenue31,720,932
Cost of Revenue-27,836,492
Gross Profit3,884,4403,884,440
 
Operating Income (+$)
Gross Profit3,884,440
Operating Expense-46,209,499
Operating Income-14,488,567-42,325,059
 
Operating Expense (+$)
Research Development938,967
Selling General Administrative9,370,216
Selling And Marketing Expenses0
Operating Expense46,209,49910,309,183
 
Net Interest Income (+$)
Interest Income1,476,640
Interest Expense-315,460
Other Finance Cost-150,651
Net Interest Income1,311,831
 
Pretax Income (+$)
Operating Income-14,488,567
Net Interest Income1,311,831
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-12,480,303-14,488,567
EBIT - interestExpense = -315,460
-12,728,376
-12,412,916
Interest Expense315,460
Earnings Before Interest and Taxes (EBIT)0-12,164,843
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-12,480,303
Tax Provision-248,073
Net Income From Continuing Ops-12,728,376-12,728,376
Net Income-12,728,376
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-1,311,831
 

Technical Analysis of Mezzion
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Mezzion. The general trend of Mezzion is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Mezzion's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Mezzion Pharma Co.Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 35,500 < 35,800 < 36,100.

The bearish price targets are: 30,050 > 29,250 > 27,000.

Tweet this
Mezzion Pharma Co.Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Mezzion Pharma Co.Ltd. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Mezzion Pharma Co.Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Mezzion Pharma Co.Ltd. The current macd is -82.51528957.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Mezzion price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Mezzion. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Mezzion price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Mezzion Pharma Co.Ltd Daily Moving Average Convergence/Divergence (MACD) ChartMezzion Pharma Co.Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Mezzion Pharma Co.Ltd. The current adx is 15.48.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Mezzion shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Mezzion Pharma Co.Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Mezzion Pharma Co.Ltd. The current sar is 33,340.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Mezzion Pharma Co.Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Mezzion Pharma Co.Ltd. The current rsi is 46.65. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Mezzion Pharma Co.Ltd Daily Relative Strength Index (RSI) ChartMezzion Pharma Co.Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Mezzion Pharma Co.Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Mezzion price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Mezzion Pharma Co.Ltd Daily Stochastic Oscillator ChartMezzion Pharma Co.Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Mezzion Pharma Co.Ltd. The current cci is -60.8974359.

Mezzion Pharma Co.Ltd Daily Commodity Channel Index (CCI) ChartMezzion Pharma Co.Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Mezzion Pharma Co.Ltd. The current cmo is -11.9615143.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Mezzion Pharma Co.Ltd Daily Chande Momentum Oscillator (CMO) ChartMezzion Pharma Co.Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Mezzion Pharma Co.Ltd. The current willr is -78.82352941.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Mezzion is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Mezzion Pharma Co.Ltd Daily Williams %R ChartMezzion Pharma Co.Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Mezzion Pharma Co.Ltd.

Mezzion Pharma Co.Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Mezzion Pharma Co.Ltd. The current atr is 1,381.

Mezzion Pharma Co.Ltd Daily Average True Range (ATR) ChartMezzion Pharma Co.Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Mezzion Pharma Co.Ltd. The current obv is 17,486,512.

Mezzion Pharma Co.Ltd Daily On-Balance Volume (OBV) ChartMezzion Pharma Co.Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Mezzion Pharma Co.Ltd. The current mfi is 26.61.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Mezzion Pharma Co.Ltd Daily Money Flow Index (MFI) ChartMezzion Pharma Co.Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Mezzion Pharma Co.Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-07-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-09MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-07-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-23ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-31STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-08-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-08-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-09-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-30BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-04ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-10-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-29BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-31ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-01STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Mezzion Pharma Co.Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Mezzion Pharma Co.Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.653
Ma 20Greater thanMa 5032,317.500
Ma 50Greater thanMa 10030,973.000
Ma 100Greater thanMa 20032,538.500
OpenGreater thanClose31,800.000
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Mezzion with someone you think should read this too:
  • Are you bullish or bearish on Mezzion? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Mezzion? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Mezzion Pharma Co.Ltd

I send you an email if I find something interesting about Mezzion Pharma Co.Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Mezzion Pharma Co.Ltd.

Receive notifications about Mezzion Pharma Co.Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.